Advertisement

Breast Cancer Research and Treatment

, Volume 99, Issue 1, pp 97–101 | Cite as

Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines

  • Marijke Wasielewski
  • Fons Elstrodt
  • Jan G.M. Klijn
  • Els M.J.J. Berns
  • Mieke Schutte
Preclinical study

Summary

The p53 tumor suppressor gene is frequently mutated in breast cancer. Here, we used direct sequencing to screen the complete coding sequence of the p53 gene from 41 human breast cancer cell lines. We identified 32 cell lines (78%) with a p53 gene alteration that predicted a change in the encoded protein. Thirty-one of these mutations were accompanied by loss of the other p53 allele. All mutations but one were unique and 27 mutations had previously been identified in uncultured human cancers. Ten mutations were predicted to encode a truncated p53 protein and 22 missense mutations were identified. p53 transcript expression was analyzed by semi-quantitative RT–PCR and p53 protein expression was determined by Western blotting. Our analyses revealed three p53 expression patterns: wild-type p53 cell lines had normal transcript levels and low or no detectable protein expression; cell lines with a p53 truncating mutation had low transcript levels and low or no detectable protein expression; and cell lines with a p53 missense mutation had highly variable transcript and protein expression levels. As a whole, our data represent a p53 mutation profile in breast cancer cell lines, providing a model for structural, functional and pharmacological studies on p53 in human cancer.

Keywords

breast cancer cell line gene mutation p53 protein expression transcript expression 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Notes

Acknowledgements

Funding was provided by Erasmus MC Revolving Fund and by the Dutch Cancer Society.

References

  1. 1.
    Vogelstein B, Lane D, Levine AJ: Surfing the p53 network Nature 408(6810): 307–310, 2000PubMedCrossRefGoogle Scholar
  2. 2.
    Borresen-Dale AL: TP53 and breast cancer Hum Mutat 21(3): 292–300, 2003PubMedCrossRefGoogle Scholar
  3. 3.
    Runnebaum IB, Nagarajan M, Bowman M, Soto D, Sukumar S: Mutations in p53 as potential molecular markers for human breast cancer Proc Natl Acad Sci USA 88(23): 10657–10661, 1991PubMedCrossRefGoogle Scholar
  4. 4.
    Concin N, Zeillinger C, Tong D, Stimpfl M, Konig M, Printz D, Stonek F, Schneeberger C, Hefler L, Kainz C, et al: Comparison of p53 mutational status with mRNA and protein expression in a panel of 24 human breast carcinoma cell lines Breast Cancer Res Treat 79(1): 37–46, 2003PubMedCrossRefGoogle Scholar
  5. 5.
    Ruiz-Ruiz MC, Lopez-Rivas A: p53-mediated up-regulation of CD95 is not involved in genotoxic drug-induced apoptosis of human breast tumor cells Cell Death Differ 6(3): 271–280, 1999PubMedCrossRefGoogle Scholar
  6. 6.
    van de Wetering M, Barker N, Harkes IC, van der Heyden M, Dijk NJ, Hollestelle A, Klijn JG, Clevers H, Schutte M: Mutant E-cadherin breast cancer cells do not display constitutive Wnt signaling Cancer Res 61(1): 278–284, 2001PubMedGoogle Scholar
  7. 7.
    Harkes IC, Elstrodt F, Dinjens WN, Molier M, Klijn JG, Berns EM, Schutte M: Allelotype of 28 human breast cancer cell lines and xenografts Br J Cancer 89(12): 2289–2292, 2003PubMedCrossRefGoogle Scholar
  8. 8.
    Carbone D, Chiba I, Mitsudomi T: Polymorphism at codon 213 within the p53 gene Oncogene 6(9): 1691–1692, 1991PubMedGoogle Scholar
  9. 9.
    Beckman G, Birgander R, Sjalander A, Saha N, Holmberg PA, Kivela A, Beckman L: Is p53 polymorphism maintained by natural selection? Hum Hered 44(5): 266–270, 1994PubMedCrossRefGoogle Scholar
  10. 10.
    Teng DH, Perry WL 3rd, Hogan JK, Baumgard M, Bell R, Berry S, Davis T, Frank D, Frye C, Hattier T, et al: Human mitogen-activated protein kinase kinase 4 as a candidate tumor suppressor Cancer Res 57(19): 4177–4182, 1997PubMedGoogle Scholar
  11. 11.
    Su GH, Hilgers W, Shekher MC, Tang DJ, Yeo CJ, Hruban RH, Kern SE: Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor suppressor gene Cancer Res 58(11): 2339–2342, 1998PubMedGoogle Scholar
  12. 12.
    Su GH, Song JJ, Repasky EA, Schutte M, Kern SE: Mutation rate of MAP2K4/MKK4 in breast carcinoma Hum Mutat 19(1): 81-84, 2002PubMedCrossRefGoogle Scholar
  13. 13.
    Prives C, Hall PA: The p53 pathway J Pathol 187(1): 112–126, 1999PubMedCrossRefGoogle Scholar
  14. 14.
    Momand J, Zambetti GP: Mdm-2: “big brother” of p53 J Cell Biochem 64(3): 343–352, 1997PubMedCrossRefGoogle Scholar
  15. 15.
    Culbertson MR.: RNA surveillance. Unforeseen consequences for gene expression, inherited genetic disorders and cancerTrends Genet 15(2): 74–80, 1999PubMedCrossRefGoogle Scholar
  16. 16.
    Berns EM, Foekens JA, Vossen R, Look MP, Devilee P, Henzen-Logmans SC, van Staveren IL, van Putten WL, Inganas M, Meijer-van Gelder ME, et al: Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer Cancer Res 60(8): 2155–2162, 2000PubMedGoogle Scholar
  17. 17.
    Norberg T, Lennerstrand J, Inganas M, Bergh J: Comparison between p53 protein measurements using the luminometric immunoassay and immunohistochemistry with detection of p53 gene mutations using cDNA sequencing in human breast tumors Int J Cancer 79(4): 376–383, 1998PubMedCrossRefGoogle Scholar
  18. 18.
    Cho Y, Gorina S, Jeffrey PD, Pavletich NP: Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations Science 265(5170): 346–355, 1994PubMedCrossRefGoogle Scholar
  19. 19.
    Rainwater R, Parks D, Anderson ME, Tegtmeyer P, Mann K: Role of cysteine residues in regulation of p53 function Mol Cell Biol 15(7): 3892–3903, 1995PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  • Marijke Wasielewski
    • 1
  • Fons Elstrodt
    • 1
  • Jan G.M. Klijn
    • 1
  • Els M.J.J. Berns
    • 1
  • Mieke Schutte
    • 1
  1. 1.Department of Medical OncologyJosephine Nefkens Institute, Erasmus University Medical CenterRotterdamThe Netherlands

Personalised recommendations